News

Releases

28. March, 2025

Annual General Meeting in Cessatech A/S

Link to Release: Minutes-AGM

Read more

Facts

6. March, 2025

Paediatric ED pain is still undertreated – the need for training and more treatment options

Pediatric pain management is a constantly developing field. Despite extensive research, several studies have...

Read more

Releases

28. February, 2025

Annual Report 2024

Today, Friday 28. February, Cessatech has released the Annual Report for 20024. We have...

Read more

Releases

4. February, 2025

Positive Notified Body opinion under MDR for CT001

On 4 February – Cessatech A/S (“Cessatech” or “the Company”) announces that the Company...

Read more

Releases

16. October, 2024

Halfway milestone patient recruitment in Paediatric Study 0202

Cessatech announces that recruitment has today reached the halfway point for patient recruitment with...

Read more

Releases

26. August, 2024

Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001

Cessatech and Proveca enter an exclusive agreement for the commercialization of CT001 world-wide excluding...

Read more

Releases

12. August, 2024

Cessatech extends Loan Facility Agreement to DKK 10 million…

Cessatech extends its undrawn Loan Facility Agreement to DKK 10 million to support the...

Read more

Releases

5. July, 2024

Anders Dyhr Dombernowsky-Toft appointed to the Board of Directors

Cessatech has today appointed Anders Dyhr Dombernowsky-Toft to the Board of Directors at the...

Read more

Releases

28. June, 2024

New data on paediatric pain relief at the PAGE conference in Rome favouring its lead candidate CT001

On 28 June – Cessatech A/S (“Cessatech” or “the Company”) announces that the presentation...

Read more

Releases

3. June, 2024

Cessatech announces superior simulated pain efficacy in children

Cessatech announces the final simulated efficacy data in children with CT001 from the abstract...

Read more

Releases

27. May, 2024

Cessatech reports first patient dosed in final Safety Study 0202 of lead product candidate CT001

Cessatech A/S announces that the Safety Study 0202 has now been initiated with dosing...

Read more

Facts

18. March, 2024

Acute pain treatment – large unmet need, paediatrics receive least…mainly due to inadequate solutions

More than 20 million children annually, alone in Europe, are subject to acute pain...

Read more

Stay up to date!

Subscribe and get notified on Cessatech's latest news.
An acceptance email will be sent to you, please check your spam.